Atea Pharmaceuticals, Inc. Expense Breakdown
No Expense Breakdown for AVIR on this site yet.
- 2026-06-30: HCV External Costs $17.92M; Compensation and Related Expenses $4.67M; HEV External Costs $2.91M; Consulting and Professional Fees $502.00K.
- 2025-06-30: HCV External Costs $24.29M; Compensation and Related Expenses $4.42M; HEV External Costs $0.00; Consulting and Professional Fees $568.00K.
Source checked: the stored Expense Breakdown page for AVIR.
Expenses by product
Research And Development Expense Net: each quarter (3 month)
| Quarter end | HCV External Costs | Compensation and Related Expenses | HEV External Costs | Consulting and Professional Fees | Other Research and Development Expenses | Early Stage Discovery External Costs | Others |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.92M | $4.67M | $2.91M | $502.00K | $385.00K | COVID Nineteen External Costs $0.00 | |
| 2025-06-30 | $24.29M | $4.42M | $0.00 | $568.00K | $397.00K | $265.00K | COVID Nineteen External Costs -$78.00K |
General and Administrative Expense: each quarter (3 month)
| Quarter end | Compensation and Related Expenses | Consulting and Professional Fees | Other General and Administrative |
|---|---|---|---|
| 2026-06-30 | $2.31M | $2.67M | $345.00K |
| 2025-06-30 | $2.21M | $4.18M | $425.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |